RT Journal Article
SR Electronic
T1 Inhaled Prostacyclin Improves Oxygenation in Patients with COVID-19-induced Acute Respiratory Distress Syndrome
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.15.21266343
DO 10.1101/2021.11.15.21266343
A1 Helene A. Haeberle
A1 Stefanie Calov
A1 Peter Martus
A1 Lina Maria Serna Higuita
A1 Michael Koeppen
A1 Almuth Goll
A1 Alexander Zarbock
A1 Melanie Meersch
A1 Raphael Weiss
A1 Martin Mehrländer
A1 Gernot Marx
A1 Christian Putensen
A1 Bernhard Nieswandt
A1 Valbona Mirakaj
A1 Peter Rosenberger
YR 2021
UL http://medrxiv.org/content/early/2021/11/16/2021.11.15.21266343.abstract
AB Background Acute Respiratory Distress Syndrome (ARDS) results in significant hypoxia, and ARDS is the central pathology of COVID-19. Inhaled prostacyclin has been proposed as a therapy for ARDS, but data regarding its role in this syndrome are unavailable. Therefore, we investigated whether inhaled prostacyclin would affect the oxygenation and survival of patients suffering from ARDS.Methods We performed a prospective randomized controlled single-blind multicenter trial across Germany. The trial was conducted from March 2019 with final follow-up on 12th of August 2021. Patients with moderate to severe ARDS were included and randomized to receive either inhaled prostacyclin (3 times/day for 5 days) or sodium chloride. The primary outcome was the oxygenation index in the intervention and control groups on Day 5 of therapy. Secondary outcomes were mortality, secondary organ failure, disease severity and adverse events.Findings Of 707 patients approached 150 patients were randomized to receive inhaled prostacyclin (n=73) or sodium chloride (n=77). Data from 144 patients were analyzed. The baseline oxygenation index did not differ between groups. The primary analysis of the study was negative, and prostacyclin improved oxygenation by 20 mmHg more than NaCl (p=0·17). Oxygenation was significantly improved in patients with ARDS who were COVID-19-positive (34 mmHg, p=0·04). Mortality did not differ between groups. Secondary organ failure and adverse events were similar in the intervention and control groups.Interpretation Although the primary result of our study was negative, our data suggest that inhaled prostacyclin might be a more beneficial treatment than standard care for patients with ARDS.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT03111212Funding StatementThe study was funded by the AKF Program of the University of Tuebingen (Grant No 414-0-0) and by TR240 grant with project number 374031971 of the Deutsche Forschungsgemeinschaft (DFG; German Research Foundation; TP B07 to P.R, B.N. and TP B08 to V.M.). Also in parts this work was supported by grant DFG-RO 3671/8-1 to P.R and by DFG-MI 1506/4-2 to V.M. This work was also funded by German Research Foundation KFO342-1 to A.Z.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Review Board of the Research Ethics Committee of the University of Tuebingen (899/2018AMG1) and the corresponding ethical review boards of all participating centers. The trial was also approved by the Federal Institute for Drugs and Medical Devices (BfArM, EudraCT No. 2016-003168-37)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors